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Research Article
Expression of AXL receptor tyrosine kinase relates to
monocyte dysfunction and severity of cirrhosis
Robert Brenig1,2 , Oltin T Pop2,3, Evangelos Triantafyllou3,4 , Anne Geng1, Arjuna Singanayagam3,4 ,
Christian Perez-Shibayama2,5, Lenka Besse6, Jovana Cupovic5, Patrizia Künzler2 , Tuyana Boldanova1, Stephan Brand2,
David Semela2, François HT Duong1, Christopher J Weston7 , Burkhard Ludewig5, Markus H Heim1 , Julia Wendon3,
Charalambos G Antoniades3,4, Christine Bernsmeier1,2
Infectious complications in patients with cirrhosis frequently
initiate episodes of decompensation and substantially contribute
to the high mortality. Mechanisms of the underlying immune-
paresis remain underexplored. TAM receptors (TYRO3/AXL/MERTK)
are important inhibitors of innate immune responses. To un-
derstand the pathophysiology of immuneparesis in cirrhosis, we
detailed TAM receptor expression in relation to monocyte function
and disease severity prior to the onset of acute decompensation.
TNF-α/IL-6 responses to lipopolysaccharide were attenuated in
monocytes from patients with cirrhosis (n = 96) compared with
controls (n = 27) and decreased in parallel with disease severity.
Concurrently, an AXL-expressing (AXL+) monocyte population ex-
panded. AXL+ cells (CD14+CD16highHLA-DRhigh) were characterised
by attenuated TNF-α/IL-6 responses and T cell activation but
enhanced efferocytosis and preserved phagocytosis of Escherichia
coli. Their expansion correlated with disease severity, complica-
tions, infection, and 1-yr mortality. AXL+ monocytes were gener-
ated in response to microbial products and efferocytosis in vitro.
AXL kinase inhibition and down-regulation reversed attenuated
monocyte inflammatory responses in cirrhosis ex vivo. AXL may
thus serve as prognostic marker and deserves evaluation as im-
munotherapeutic target in cirrhosis.
DOI 10.26508/lsa.201900465 | Received 21 June 2019 | Revised 7 November
2019 | Accepted 2 December 2019 | Published online 10 December 2019
Introduction
Patients with cirrhosis are at increased risk of infection and con-
sequent acute decompensation (AD) with substantially elevated
morbidity and mortality (1). Compared with the overall rate of in-
fections in hospitalised patients (5–7%), bacterial infections occur
significantly more frequently in patients with cirrhosis (32–34%) (2, 3).
Similarly, infections account for more than 50% of hospitalisations in
cirrhotic patients, are the main precipitant for AD without and with
organ failure (acute-on-chronic liver failure [ACLF]) (4, 5), and impli-
cate a highmortality (2, 6). Infection susceptibility in cirrhosis has been
attributed to a state of immuneparesis, defined by inadequate im-
mune responses to microbial challenge (7, 8, 9).
The pathophysiology of immuneparesis in cirrhosis is highly
complex and remains incompletely understood, involving diverse
defects in immune cell function, including monocytes, and soluble
factors in multiple compartments (7). Circulating monocytes from
patients with AD and ACLF compared with stable cirrhosis demon-
strated reduced expression of HLA-DR and attenuated production of
TNF-α/IL-6 in response to lipopolysaccharide (LPS), which has pre-
viously been linked to adverse outcome (10, 11, 12). Moreover, the role
of bacterial translocation in the pathogenesis of immune dysfunction
and infection susceptibility has been highlighted (13, 14).
TAM receptors (TYRO3, AXL, and MERTK) belong to the family of
receptor tyrosine kinases. Among immune cells, they are expressed
on monocytes, macrophages, dendritic cells, and glial cells, and
additionally on epithelial cells of the reproductive system, the
retina, and tumour cells (15). TAM receptors are important regu-
lators of innate immune homeostasis, acting by inhibition of TLR
signalling pathways through a signal transducer and activator of
transcription 1 (STAT1)- and suppressors of cytokine signalling
(SOCS1/3)-dependent mechanism (15, 16) and by promotion of
phagocytic removal of apoptotic cells (efferocytosis) (16). Their
activation succeeds ligand binding (growth arrest–specific gene-6
[GAS6], PROTEIN S) and interaction with phosphatidylserine on
apoptotic cells (15, 16, 17). In murine dendritic cells, activation re-
quired interaction with the type I interferon receptor (IFNAR) (16).
We recently identified the expansion of MERTK-expressing mono-
cytes and macrophages in diverse compartments in patients with ACLF
that dampened innate immune responses to microbial challenge and
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conferred disease severity and adverse outcomes (18). The expansion
of MERTK-expressing monocytes and macrophages was moreover
detected in acute liver failure (18) and characterised by both
suppressed immune responses and enhanced efferocytic capac-
ities (19). Another immune-suppressive population, expanded in
the circulation of patients with ACLF, was monocytic myeloid–
derived suppressor cells (M-MDSC) that suppressed T cell activa-
tion, innate immune responses, and pathogen uptake (20).
It is not clear when and/or under which circumstances immu-
neparesis and monocyte dysfunction occurs with an associated
susceptibility to infection during the clinical course of cirrhosis and
portal hypertension, before the onset of AD. The main emphasis of
this study is to detail the expression of TAM receptors onmonocytes
in relation to monocyte function and disease severity of patients
with cirrhosis in the absence of AD using patients with AD, chronic
liver disease (CLD) without cirrhosis and healthy controls (HCs) as
comparators. We hereby seek to better understand the patho-
physiology of immuneparesis development in patients with cir-
rhosis prior to AD and identify candidates for biomarkers and future
immunotherapeutic targets that may preserve innate immune
responses.
Results
Patient characteristics
Patients with cirrhosis were distinguished between Child-Pugh A, B,
and C and compared with AD, CLD without cirrhosis, and HC. The
cohort was characterised by disease severity scores, aetiologies,
and diverse clinical parameters (Tables S1 and S2). In patients with
cirrhosis without AD, 1-yr mortality rate was 4.5% and rising with
Child-Pugh stage: A (0%), B (5.7%), and C (11.8%). 1-yr mortality rate
for those with AD was 75%, with two of eight patients dying within 28
d of enrolment. N = 9 patients deceased from cirrhosis-related
complications during follow-up of 1 yr (secondary infections [n = 4],
ACLF with multiorgan failure [n = 3], hepatocellular carcinoma [HCC]
[n = 1], hypovolemic shock due to variceal bleeding [n = 1]), and the
cause of one death was unknown. Current infections at hospital
admission were seen in 62.5% of patients with AD. Within 4 wk
following inclusion into the study, 5.2% of patients (Child B: 5.7%,
Child C: 5.9%, and AD 25%) developed infectious complications,
adapted from the definition by Bajaj et al (9). Episodes of AD de-
veloped in 10.2% of cirrhotic patients (Child B: 17.1% and Child C:
17.6%) within 4 mo following inclusion (Table S1).
Innate immune responses are impaired in patients with cirrhosis
and parallel the expansion of an AXL-expressing circulating
monocyte population
In patients with AD/ACLF, we recently described impaired in-
flammatory cytokine production of circulating monocytes to mi-
crobial challenges (18, 20). Attenuated responses were also seen in
stable cirrhotic patients (18, 20). It, however, remained unknown
when and to what extent circulating monocytes develop immune
dysfunction over the time course of disease progression. We
measured ex vivo inflammatory cytokine production upon LPS
treatment of circulating monocytes from patients with cirrhosis at
different stages of disease. TNF-α and IL-6 production was reduced
in cirrhosis compared with HC and incrementally decreased from
Child A to C, and AD but remained preserved in patients with CLD
without cirrhosis (Fig 1A and B).
In parallel with increased disease severity and the decline of
inflammatory cytokine production in response to LPS, we dem-
onstrated the expansion of an AXL-expressing monocyte pop-
ulation ex vivo in the circulation of patients with cirrhosis (Figs 1C
and S1A). The occurrence of AXL-expressing monocytes was in-
dependent of the underlying aetiology and other potential con-
founders (inpatient treatment, current infection, antimicrobial
treatment, immunosuppressive therapy, and non-metastatic ma-
lignancies; Fig S1B and D). Within monocyte subsets, the expression
of AXL was highest in but not restricted to the intermediate subset
(cluster of differentiation [CD]14++CD16+) (Fig S2A). AXL expression
on monocytes of patients with CLD without cirrhosis was low; a
similar pattern was also seen in AD (Fig 1C). Other immune cells
such as lymphocytes and granulocytes barely expressed AXL (Fig
S2B). Longitudinal follow-up data showed an increase in AXL
expression after re-compensation of AD episodes and a change
in AXL expression paralleling the evolution of disease severity
after 1 yr (Fig S1E and F). Recently, we described a MERTK-expressing
monocyte population that was expanded in the circulation of pa-
tients with AD/ACLF (18), which was again confirmed in this cohort
(Fig 1D). In CLD with and without compensated cirrhosis, however,
MERTK and TYRO3 expressions were sparse (Figs 1D and E, and S1A).
Circulatory plasma levels of the AXL ligand GAS6 were significantly
elevated in cirrhosis compared with HC, independent of the aeti-
ology. GAS6 increased from Child A to C and correlated with AXL-
expressing monocytes (Figs 1F and S1C).
Circulating AXL-expressing monocytes in patients with advanced
cirrhosis indicate diseases severity, complications, and poor
outcome
We next assessed the expansion of AXL-expressing monocytes in
relation to clinical parameters, disease severity scores, in-
dicators of complications, and outcome. The proportion of AXL-
expressing monocytes strongly correlated with Child-Pugh and
model for end-stage liver disease (MELD) scores and the clas-
sification of cirrhosis established by D’Amico et al (21) (Fig 2A).
AXL-expressing monocytes also correlated with soluble AXL
(sAXL) plasma levels. sAXL was significantly elevated in cirrhosis
compared with controls, independent of the underlying aetiol-
ogy, correlated with Child-Pugh and MELD, and predicted the
onset of AD episodes within 4 mo following study inclusion
(Fig S3A–E).
AXL on monocytes predicted 1-yr mortality with a sensitivity of
80% and specificity of 79.2% for the criterion median fluorescence
intensity (MFI) > 440. AXL moreover predicted the onset of AD within
4mo following inclusion, and the development of infection over the
next 4 wk. AXL was also associated with C-reactive protein (CRP)
(Figs 2B and S4A, and B). Furthermore, AXL-expressing monocytes
were associated with manifestations of portal hypertension (ascites,
hepatic venous pressure gradient, varices, hepatic encephalopathy,
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Figure 1. TAM (TYRO3, AXL, and MERTK) receptor expression and functional characterisation of circulating monocytes in cirrhosis.
(A) FACS gating strategy used to identify circulating monocytes in whole blood or PBMCs (left panel). Side scatter (SSC), forward scatter (FSC). Monocyte counts
(differential leucocyte count, right panel). (B) TNF-α– and IL-6–producingmonocytes (%) in response to LPS ex vivo at different stages of cirrhosis and representative FACS
histograms (HC, Child C, and isotype). (C, D, E) TAM receptor expression on circulatingmonocytes (%) at different stages of cirrhosis and representative FACS histograms for
AXL expression (HC, Child C, and fluorescence minus one). (F) GAS6 levels (pg/ml) in HC and cirrhosis (upper panel) and in correlation with AXL expression (% of
monocytes, lower panel). HC n = 27, CLD without (w/o) cirrhosis n = 8, Child A n = 36, Child B n = 28, Child C n = 17, and acute decompensation (AD) of cirrhosis n = 8. Data are
presented as box plots showing median with 10–90 percentile. *P < 0.05/**P < 0.01 (Mann–Whitney tests, Spearman correlation coefficient).
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Figure 2. The AXL-expressing monocyte population in patients with cirrhosis in relation to disease severity, complications and prognosis.
(A) Correlations of AXL-expressing monocytes (%) with Child-Pugh (n = 78) and MELD (n = 73) scores and the classification by D’Amico et al (21). HC, CLD without (w/o)
cirrhosis. Box plots showing median/10–90 percentile. (B) AXL expression predicted 1-yr mortality (criterion MFI > 440, sensitivity 80%, specificity 79.2%), development of
further episodes of AD of cirrhosis within 4 mo (criterion MFI > 362, sensitivity 66.7%, specificity 67.1%), and development of infection over 4 wk (criterion MFI > 389,
sensitivity 60%, specificity 65.5%). Median/interquartile range (IQR). (C, D) AXL-expressing monocytes in relation to portal hypertension (C: ascites, hepatic venous
pressure [HVPG, n = 14], varices, hepatic encephalopathy; D: bilirubin, n = 72; INR, n = 74; albumin, n = 72; and creatinine, n = 75). Median/10–90 percentile. *P < 0.05/**P < 0.01
(Mann–Whitney tests, Spearman correlation coefficient).
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and renal dysfunction) and correlated with individual parameters
of liver function (bilirubin, international normalised ratio [INR],
albumin) (Fig 2C and D). High AXL expression on monocytes may
albeit small numbers also predict the need for transplantation,
transplantation-free 1-yr survival, and development of HCC within
1 yr (Fig S4C–E).
Phenotype of circulating monocytes in patients with cirrhosis and
the AXL-expressing monocyte population
Monocytes from patients with CLD without cirrhosis did not differ
phenotypically from HC. Monocytes from patients with cirrhosis,
however, showed an HLA-DRlow phenotype with decreased ex-
pression of Fcγ- and homing receptors (CD32lowCX3CR1lowCCR7low).
HLA-DR expression significantly decreased from Child A to C (Fig
S5A).
Within this entire population, the expanded subset of AXL-
expressing monocytes (AXL+) (Fig 3A) were CD14+CD16highHLA-
DRhigh indicating a mature monocyte subpopulation with augmented
expression of Fcγ-receptor CD32, TLR4, and homing/chemokine re-
ceptors (CCR5, CCR7, and CX3CR1) (Fig 3B). There was no difference in
viability between AXL+- and AXL−-monocytes (Fig 3C).
Importantly, the CD14+HLA-DR+AXL+ immune cell subset detailed
here has to be distinguished from the recently identified immu-
nosuppressive M-MDSCs in patients with cirrhosis and ACLF (20),
which we observed expanding from Child A to C in our cohort.
M-MDSCs were CD14+CD15−CD11b+HLA-DRlow/neg, as previously de-
fined (22), and expressed lower levels of AXL in comparison with
CD14+HLA-DR+ monocytes (Fig S6A–C).
AXL-expressing circulating monocytes contribute to impaired
innate immune responses and suppression of T cell proliferation
while retaining phagocytic capabilities for bacteria ex vivo
To investigate the effect of the expanded CD14+HLA-DR+AXL+ subset
on the impaired inflammatory cytokine responses observed in
monocytes from patients with cirrhosis we assessed the functional
properties of AXL+ monocytes ex vivo.
Detailed analyses of the distinct subsets revealed that TNF-α/
IL-6 production in response to LPS was decreased in both CD14+HLA-
DR+AXL+ monocytes and M-MDSCs when compared with CD14+HLA-
DR+AXL− monocytes from patients with cirrhosis and HC. In detail,
TNF-α production decreased from 59.2% (13.8) to 40% (34.6) of
monocytes in CD14+HLA-DR+AXL− from HC versus CD14+HLA-DR+AXL+
from patients (MFI: 2665 [1668] versus 1117 [2812]) and IL-6 from
73.7% (37.3) to 40% (55) (MFI: 1909 [1702] versus 408 [298]; median
[interquartile range, IQR]) Figs 4A and S7A, and B). The CD14+HLA-
DR+AXL− population represented the majority of monocytes in HC,
indicating it may be regarded “functionally intact” but was se-
quentially lost in the circulation of patients with progression of
cirrhosis (Fig S6B). In line with previous data detailing TAM re-
ceptor signalling pathways (16), we observed higher mRNA levels
of SOCS1/SOCS3 in monocytes of Child B/C patients, compared
with HC (Fig 4B). Our data thus reveals the determination of
functional roles of monocyte subsets in a pathophysiological
context such as cirrhosis.
We further revealed that AXL expression on monocytes in cirrhosis
was associatedwith inhibition of T cell proliferation, when tested in an
allogeneic mixed lymphocyte reaction (Fig 4C).
Ex vivo phagocytic capacity of Escherichia coli (E. coli) bioparticles
and live GFP-containing E. coli by circulating monocytes did not differ
between cirrhotic patients and HC. AXL+ monocytes showed preserved
phagocytosis capacities for E. coli bioparticles and live E. coli bacteria,
whereas M-MDSCs revealed reduced phagocytosis, when compared
with CD14+HLA-DR+AXL− monocytes from patients with cirrhosis and
HC (Figs 4D and S7C).
Considering these observations, the expanded CD14+HLA-DR+AXL+
monocyte population in the circulation of patients with cirrhosis
(notably, not existing in healthy subjects) remained functionally
phagocytic, but prevented T cell proliferation and inflammation
(low TNF-α/IL-6 production) in a presumably SOCS1/3-dependent
manner, representing an immune-regulatory “homeostatic”monocyte
population expanding during cirrhosis progression.
AXL overexpression in THP-1 cells attenuates LPS-induced
inflammatory cytokine production in vitro
As proof-of-concept for the observations developed above, in vitro,
we overexpressed AXL in the monocytic THP-1 cell line using a
retroviral system (Fig 5A). Following transduction, AXL mRNA ex-
pression (2.2 ± 0.3-fold; Fig S8A) and protein levels (88% THP-1-AXL+
cells; Fig 5A and B) were increased. Phenotypic characterisation of
the THP-1-AXL+ model cell line is illustrated in Fig S8B. Consistent
with the observations in patients with cirrhosis ex vivo, AXL-
expressing THP-1 cells produced less TNF-α and IL-6 in response
to LPS when compared with non-transduced THP-1 cells (Fig 5C).
Pathogen-associated molecular patterns (PAMPs), cytokines,
bacterial uptake, and efferocytosis induce AXL up-regulation on
monocytes
Next, we sought to understand the mechanisms leading to the
expansion of the described immune-regulatory AXL-expressing
monocyte population. Pathophysiologically, cirrhosis progression
involves development of portal hypertension and subsequent
pathologic bacterial translocation facilitates microbial products
accessing the systemic circulation (8, 13, 14, 23). Hence, we tested
PAMPs and damage-associated molecular patterns (DAMPs) for
their ability to modify monocyte differentiation and AXL expression
in vitro. Stimulation with bacterial products such as TLR ligands
(Pam3SK4, LPS, CpG, and poly (I:C)) significantly up-regulated AXL
expression in vitro. Similarly, pro-inflammatory factors (IFN-α and
TNF-α) induced AXL up-regulation. In contrast, the DAMP high-
mobility group protein B1 (HMGB1), TGF-β, and AXL ligand GAS6
did not induce AXL expression. LPS-induced up-regulation of AXL
was time dependent (Fig 6A), and those monocytes produced
significantly less TNF-α/IL-6 upon LPS when compared with mono-
cytes without prior LPS exposure (Fig S9A). Notably, monocytes
incubated with 25% plasma of cirrhosis patients did not show
biologically relevant changes in AXL expression (Fig 6B), suggesting
that additional factors are required to generate this subset in vivo.
Phagocytosis is required for efficient clearance of pathogenic
microorganisms and initiation of various immune responses. AXL+
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monocytes exhibited preserved phagocytosis capacities (Figs 4D
and S7C) and AXL expression significantly increased on monocytes
after phagocytosis of E. coli and Staphylococcus aureus (S. aureus)
bioparticles as well as of live GFP-E. coli bacteria (Fig 6C). Phago-
cytosis capacity of E. coli bioparticles positively correlated with the
degree of AXL expression and concurrently negatively with TNF-α
production (Fig S7D–E).
Within inflammatory milieus, as prevalent in different com-
partments of patients with cirrhosis (8), efferocytosis is required to
maintain immune homeostasis (24, 25). We, therefore, co-cultured
healthy monocytes with neutrophils and HepG2 cells previously
labelled with a cytoplasmic cell-tracker and then induced to ap-
optosis (19, 26). AXL expression on monocytes was up-regulated
following co-culture with apoptotic cells. Monocytes that engulfed
apoptotic cells (efferocytosing) were characterised by higher AXL
expression, compared with monocytes that did not (resting). AXL+
monocytes showed higher efferocytosis capacity than AXL−monocytes
when co-cultured with apoptotic neutrophils (Fig 6D); following
efferocytosis of neutrophils, AXL+ monocytes produced less TNF-
α/IL-6 upon LPS than AXL− monocytes (Fig S9B), supporting the
Figure 3. Phenotypic characterisation of the AXL-expressing monocyte subset.
(A) Gating strategy with representative FACS scatter plots and histograms for AXL expression used to distinguish AXL-expressing (AXL+) from AXL-negative (AXL−)
monocytes. Side scatter (SSC), forward scatter (FSC), fluorescence minus one. (B) Immunophenotyping of AXL+ and AXL− monocytes in cirrhosis. Glycoprotein CD14, MHC
class II receptor HLA-DR, Fcγ-receptors (CD16 and CD32), TAM receptors (MERTK and TYRO3), chemokine receptors (CX3CR1, CCR5, and CCR7), and TLR4. Box plots showing
median/10–90 percentile. (C) Viability (7-AAD−AnnexinV−-cells) of AXL+-/AXL−-monocytes. Median/10–90 percentile. *P < 0.05/**P < 0.01 (Wilcoxon tests).
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accumulation of AXL+ immune-regulatory monocytes in an inflam-
matory environment.
AXL inhibitor BGB324 and metformin restore innate immune
responses of monocytes from patients with cirrhosis ex vivo
Given the distinct immune-regulatory functions of the AXL+ monocyte
population in patients with cirrhosis and its association with disease
severity and infection, we questioned whether inhibition or down-
regulation of AXL would reverse the anti-inflammatory properties.
BGB324 is a selective small molecule inhibitor of AXL previously tested
in clinical studies (27). Metformin, a well-known antidiabetic drug,
was previously described to down-regulate AXL expression (28) and
to regulate the AXL signalling cascade in the context of cancer (29,
30). Metformin-induced down-regulation of AXL was confirmed in
monocytes from patients with cirrhosis ex vivo here. Treatment with
BGB324 did not affect AXL expression (Figs 7A and S10A). Both, BGB324
(1 μM) and metformin (10 mM) treatment restored LPS-induced TNF-α
production of monocytes from patients with cirrhosis ex vivo. When
comparing AXL+ with AXL− monocyte populations from patients with
cirrhosis following metformin treatment, cytokine production was
enhanced in AXL+ but not AXL− cells (Fig 7B). Viability of monocytes
after metformin treatment was marginally reduced (Fig S10B).
Whereas phagocytosis capacity of E. coli bioparticles was preserved
after BGB324 administration, it decreased upon metformin treat-
ment (Fig 7C).
Discussion
In this work, we detail the characteristics of circulating monocytes
in patients suffering from cirrhosis at different stages of disease
without signs of AD. We newly describe the expansion of an AXL-
expressing immune-regulatory monocyte subset (CD14+HLA-DR+AXL+)
along cirrhosis progression and its close association with disease
severity, infection susceptibility, development of AD, and prognosis.
The AXL-expressing monocyte generation was linked to the abun-
dance of PAMPs and cytokines, phagocytosis, and efferocytosis in the
context of recurrent inflammation. Our findings substantially add to
the understanding of the pathophysiology of immuneparesis in
Figure 4. Functional characterisation of AXL-
expressing circulating monocytes ex vivo.
(A) TNF-α and IL-6 production upon LPS treatment of
CD14+HLA-DR+AXL+, CD14+HLA-DR+AXL− monocytes and
M-MDSCs from HC and patients with cirrhosis (% of
monocytes). (B) SOCS1/3 mRNA-expression of
monocytes from HC and cirrhosis. (C) T cell proliferation
in co-culture with monocytes at day 2 in a mixed
lymphocyte reaction (HC versus cirrhosis; AXLlow versus
AXLhigh). Data shown as MFI−1 of carboxyfluorescein
succinimidyl ester. (D) Phagocytosis of E. coli
bioparticles of the entire monocyte population from
different patient groups (HC, CLD without [w/o] cirrhosis,
cirrhosis, left panel) and CD14+HLA-DR+AXL+,
CD14+HLA-DR+AXL− subsets, and M-MDSCs from HC and
patients with cirrhosis. Box plots showing median/
10–90 percentile. *P < 0.05/**P < 0.01 (Mann–Whitney,
Wilcoxon tests).
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cirrhosis and identify a potential biomarker and immunothera-
peutic target.
Although we and others have previously focused on impaired
innate immune responses after the onset of AD/ACLF, when in-
fection susceptibility is highest (10, 12, 18, 20), it is barely known
when and under which circumstances innate immune dysfunction
occurs and infection susceptibility emerges during progression of
cirrhosis and portal hypertension. Previous studies addressing
phenotype and function of classical (CD14+CD16−) and nonclassical
(CD14+CD16+) monocyte subsets in CLD showed inconsistent data
regarding cytokine production and phagocytosis (31, 32, 33). We
previously showed that inflammatory cytokine production was
depressed not only in AD/ACLF but also in stable cirrhosis (18),
whereas the underlying mechanism remained unexplained.
Here, we demonstrate the accumulation of circulating CD14+HLA-
DR+AXL+ monocytes with attenuated innate immune functions, that
is, decreased inflammatory cytokine production (TNF-α/IL-6) and T
cell activation, along disease progression of cirrhosis in compensated
and chronically decompensated patients. Although dysfunctional
monocytes were rarely encountered in Child A, their number sub-
stantially expanded in advanced stages (Child B/C) and displaced
functionally intact monocytes. The findings were irrespective of the
underlying aetiology. Monocyte functions were preserved in patients
with CLD without cirrhosis (F ≤ 3). Follow-up data of individual patients
showed an evolution of AXL-expressing monocytes in parallel with
disease severity scores. However, this requires further evaluation in
larger prospective longitudinal studies.
AXL is amember of TAM receptors thatmainly function as inhibitors
of TLR- and cytokine receptor–mediated monocyte/macrophage
activation and promoters of apoptotic cell removal (15, 16). Loss of
AXL expression on antigen-presenting cells has been linked to
autoimmunity (15). TAM receptors are differentially expressed and
exhibit distinct expression, regulation, and activity under specific
conditions (34, 35). Although CD14+HLA-DR+AXL+ cells accumulated
with worsening stages of cirrhosis, they disappeared upon acute
hepatic decompensation. By contrast, CD14+HLA-DR+MERTK+ mono-
cytes remained undetectable in stable cirrhosis and emerged upon
AD (18). In addition, CD14+HLA-DR+MERTK+ cells were abundant in the
circulation and the liver in acute liver failure where they were
characterised as resolution-type monocytes/macrophages (19). This
underlines the distinct and counter-regulatory roles of AXL andMERTK
in different phases of cirrhosis and inflammation. Our findings in a
human disease verify previous murine data that identified differential
and reciprocal expression and function between AXL and MERTK on
BMDMs/BMDCs (34). The authors described both receptors as
phagocytic mediators in vitro, whereas MERTK expression was in-
duced by tolerogenic stimuli and induced tolerance, and AXL was
induced by inflammatory stimuli and acted in the feedback in-
hibition of inflammation (34). The underlying differential signalling
mechanisms need to be addressed in future investigations.
Extensive characterisation of the AXL-expressing monocyte
population revealed an immune-regulatory subset that emerged in
the circulation likely to maintain immune homoeostasis despite
rising inflammatory signals during progression of cirrhosis. AXL-
expressing monocytes were characterised by increased HLA-DR,
CD16 and chemokine-receptor expression, enhanced clearance of
apoptotic cells, increased expression of Fcγ-receptor, and pre-
served phagocytosis of E. coli, but attenuated T cell activation and
secretion of pro-inflammatory cytokines (TNF-α/IL-6) after mi-
crobial challenge presumably in a SOCS1/3-dependent manner, as
previously proposed (16). Although phagocytosis of pathogens
represents the first line of defence when an organism encounters
microbes, clearance of apoptotic cells is required for immune
homeostasis during inflammation. Our findings suggest that AXL-
expressing monocytes may expand during cirrhosis and progressive
portal hypertension in response to the uptake of pathogens and
bacterial products in the setting of pathologic bacterial translocation
(8, 13, 14, 23), and to clear apoptotic cell debris accumulating in
response to chronic inflammation (15, 16). Concurrently, excessive
systemic inflammatory responses are inhibited.
Similar to our findings, a recent study described AXL-expressing
murine airway macrophages at homeostatic conditions, which
increased after influenza infection, thereby preventing excessive
tissue inflammation through efferocytosis (35). AXL expression was
critical for functional compartmentalisation, as it was not present
on interstitial lung macrophages (35). We propose that in cirrhosis,
Figure 5. AXL overexpression in THP-1 cells and LPS-
induced inflammatory cytokine production in vitro.
(A) Schematic model of retroviral transduction of THP-1
cells and representative FACS histogram of AXL
expression in THP-1-AXL+ cells. Side scatter (SSC),
forward scatter (FSC). (B) AXL expression in THP-1 cells
and AXL-expressing THP-1 cells (%). (C) TNF-α and IL-6
secretion (pg/ml) in response to LPS in THP-1-AXL+
and THP-1 cells. Bar plots showing mean/SD. *P < 0.05/
**P < 0.01 (t tests).
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Figure 6. AXL expression on monocytes in response to bacterial and inflammatory stimuli and following phagocytosis and efferocytosis.
(A) AXL expression after incubation with bacterial/inflammatory stimuli as indicated in vitro for 18 h. Time-dependent effect of LPS on AXL expression. Delta AXL
(ΔAXL) MFI shows difference to untreated cells. Bar plots showing mean/SD (t tests). (B) AXL expression after monocyte incubation in 25% plasma of HCs and
patients with cirrhosis for 24 h. (C) Representative FACS scatter plots for monocyte phagocytosis of microbial products ex vivo. Forward scatter (FSC). AXL expression
after E. coli and S. aureus bioparticle uptake (15 min) and live GFP-E. coli ingestion (60 min) on monocytes from HC and patients with cirrhosis. Box plots showing
median/10–90 percentile (Mann–Whitney tests). (D) Representative FACS scatter plots for resting (CellTracker−) and efferocytosing (CellTracker+) monocytes after
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AXLmay be operative in settings where the nature of injury is driven by
excessive pro-inflammatory responses, as present in diverse under-
lying aetiologies.
This newly described immune-regulatory, AXL-expressing mono-
cyte population must be clearly distinguished from another recently
discovered immunosuppressive cell subset that accumulated in the
circulation in stages of AD: M-MDSCs were characterised by sup-
pression of T cell activation, pathogen uptake, and TLR-elicited
pro-inflammatory responses to microbial challenge (20). Here, we
observed that M-MDSCs started to emerge also in patients with
cirrhosis without signs of AD. Considering the reduced inflammatory
responses to microbial challenge of both CD14+HLA-DR+AXL+- and
M-MDSCs compared with functionally intact CD14+HLA-DR+AXL− cells
in relation to their abundance in the circulation, we propose that
these populations together largely explain the depressed innate
immune responses of the entire monocytic population at these
stages.
Having observed AXL up-regulation on circulatory monocytes in
relation to portal hypertension, we hypothesized an underlying
mechanism involving pathologic bacterial translocation leading to
the abundance of bacterial products, PAMPs (8, 13, 14, 23), and
subsequent chronic systemic inflammation (8, 23). At the same time,
chronic liver injury leads to release of DAMPs (36). Indeed, we were
able to generate AXL-expressing monocytes with dampened innate
immune responses by stimulation with selected TLR ligands and
pro-inflammatory factors in vitro. These findings coincide with
previous data showing AXL up-regulation on murine BMDMs (34, 35)
and peritoneal macrophages (35) upon stimulation with inflam-
matory stimuli (34, 35). In contrast to M-MDSCs, generated in vitro by
culturing monocytes in ACLF plasma (20), inflammatory factors in
plasma of patients with cirrhosis were necessary, but insufficient to
induce AXL up-regulation alone. Our data support the hypothesis
that efferocytosis and phagocytosis of bacteria in the circulation
are further required to enhance AXL up-regulation on monocytes.
The stimulatory effect of pathogen uptake on AXL expression is
novel and may explain high AXL expression on circulating mono-
cytes in conditions where pathogens and their products become
abundant because of pathologic bacterial translocation such as
cirrhosis. TAM receptor activation after efferocytosis had previously
been shown on murine BMDMs/BMDCs (34).
Dissecting the complexity of differential monocyte differentia-
tion and activation of effector pathways of particular TAM receptors
on monocytes at different stages of cirrhosis will be subject to
future investigations, including the use of unbiased large-scale
techniques. In a multisystem disorder such as cirrhosis, additional
compartments such as the liver, but also the gut, the portal cir-
culation, the peritoneum, and potentially others and their tissue-
specific immune systems play crucial roles in the pathophysiology
of the underlying immuneparesis. It is the aim of our subsequent
investigations to detail the differentiation and immune function of
tissue-specificmyeloid cells in these compartments, in particular in
respect to the immune-regulatory role of TAM receptors.
Moreover, by ex vivo proof of principle experiments treating
monocytes from cirrhotic patients with the highly specific AXL inhibitor
BGB324 and metformin, which was previously described to target and
down-regulate AXL (28), innate immune responses were significantly
enhanced, suggesting AXL as potential immunotherapeutic target to
augment defence against infections. Whereas BGB324 did not nega-
tively affect phagocytic capabilities, metformin did.
BGB324 was originally developed for cancer treatment and is
currently tested in clinical Phase Ib/II trials for patients with ag-
gressive and metastatic cancers (37). Interestingly, other studies
have examined BGB324 as an anti-fibrotic agent. GAS6/AXL path-
ways were associated with fibrogenesis in CLD (38) and idiopathic
pulmonary fibrosis (39), respectively, and were reversed by BGB324.
Multi-tyrosine kinase inhibitors, including AXL, are known for their
diverse antitumour effects and are tested in phase III clinical trials
for advanced HCC (40). Distinct AXL blockage impacts on tumour
progression through immune surveillance by AXL-expressing im-
mune cells and anti-proliferative effect on AXL-expressing tumour
cells (37, 40). AXL inhibition by BGB324 may, thus, represent a
promising concept with anti-fibrotic, immune-stimulatory, and also
anti-tumour effects.
Whereas previous studies described anti-inflammatory, presumably
AXL-independent properties of metformin on myeloid cells (41), we
observed enhanced immune responses of AXL-expressing monocytes
from cirrhotic patients after metformin treatment. Metformin, con-
ventionally used as anti-diabetic drug, exerts various pleiotropic ef-
fects acting via diverse downstream signalling pathways (42) and has
been reported to be associated with reduced HCC incidence (43) and
reduced portal hypertension in cirrhosis models (44). Further studies
hint at a potential regulatory effect ofmetformin on the AXL cascade in
the context of cancer (29, 30). As an inexpensive, well-established
drug, metformin may represent an interesting immunomodulatory
treatment option for patients with cirrhosis and no signs of AD,
when AXL-expressing monocytes are frequent and the risk for
metformin-associated lactic acidosis is low. Our data are suggestive
to further investigate the potential significance of metformin in this
context and its underlying signalling mechanism.
As these substances were only tested ex vivo here, subsequent in
vivo studies in rodent models are required to systematically in-
vestigate target- and off-target effects such as auto-immunity or
uncontrolled inflammation. We showed previously that inhibition
of MERTK on monocytes of AD/ACLF patients reversed innate im-
mune dysfunction (18). Given the distinct and reciprocal expression
profiles of AXL and MERTK in cirrhosis, it further needs to be
addressed which receptor to target at which stage of disease and in
which compartment.
Finally, strong correlations of AXL expression on monocytes with
disease severity and prognosis, that is, i.e. development of in-
fection, episodes of AD, and 1-yr mortality underline its clinical
significance. Two recent studies suggested sAXL as a serum bio-
marker for advanced liver fibrosis, cirrhosis, and HCC (45, 46). Here,
we observed strong correlations of AXL-expressing monocytes with
co-culture with apoptotic cells for 8 h. Apoptosis of neutrophils and HepG2 cells after 24 h. AXL expression after efferocytosis, AXL expression of resting and
efferocytosing monocytes, and efferocytosis capacity for neutrophils of AXL+-/AXL−-monocytes. Bar plots showing mean/SD. *P < 0.05/**P < 0.01 (unpaired/paired
t tests).
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Figure 7. Innate immune responses and phagocytosis capacity of monocytes from patients with cirrhosis after AXL inhibition and down-regulation ex vivo.
(A, B, C) AXL expression (% of monocytes), (B) TNF-α and IL-6 production in response to LPS (total monocyte population and AXL+/AXL−-cells), and (C) monocyte
phagocytosis capacity of E. coli bioparticles (%CD14+ cells) after small molecule inhibitor BGB324 and metformin treatment compared with untreated cells (w/o) in HCs
and patients with cirrhosis. Box plots showing median/10–90 percentile. *P < 0.05/**P < 0.01 (Mann–Whitney, Wilcoxon tests).
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the shed receptor sAXL and also liver disease severity scores. Based
on our findings, the number of AXL-expressing monocytes in blood
count may represent a prognostic biomarker for immuneparesis
and cirrhosis and validates further evaluation.
In conclusion, the number of AXL-expressing immune-regulatory
monocytes in the circulation of patients with cirrhosis indicated
disease severity, immuneparesis, infection susceptibility, AD, and
mortality. CD14+HLA-DR+AXL+ monocytes were expanded upon
PAMP and cytokine exposure, pathogen,- and apoptotic cell uptake
and hallmarked by preserved phagocytosis and enhanced effer-
ocytosis but reduced cytokine production and T cell activation,
implying a role in immune homeostasis in a condition defined by
pathologic bacterial translocation and recurrent inflammation.
Immunotherapeutic modulation of AXL may represent an option
deserving evaluation to augment immune responses and reduce
infection susceptibility, morbidity, and mortality in cirrhosis.
Materials and Methods
Patients and sampling
A cohort of 96 patients with cirrhosis was identified at the Cantonal
Hospital St. Gallen and the University Hospital Basel, Switzerland,
between January 2016 and May 2019. Patients were recruited during
consultations (Child-Pugh A [n = 36], B [n = 35], C [n = 17]), re-
spectively, categorised according to Child-Pugh and European
Association for the Study of the Liver - Chronic Liver Failure (EASL-
CLIF) Consortium scores (47). We included HC (n = 27), patients with
CLD without cirrhosis (n = 8; Metavir F ≤ 3), and patients with AD
within 24 h following hospital admission (n = 8) as comparators.
Healthy volunteers from the regions St. Gallen and Basel, Swit-
zerland, were matched by age and sex and served as HCs. Patients’
assent was obtained by the patients’ nominated next of kin if they
were unable to provide informed consent themselves. Cirrhosis was
diagnosed by liver biopsy (n = 92, 95.8%) or clinical presentation
with typical ultrasound (n = 4, 4.2%). Exclusion criteria for patients
were age younger than 18 yr and evidence of metastatic malig-
nancies (including HCC). Five patients with non-metastatic malig-
nancies were included (HCC, Barcelona Clinic Liver Cancer staging
system stages A–B [n = 3]; breast cancer, pT1b, pN0, and M0 [n = 1];
prostate carcinoma, Gleason score 7a [n = 1]). Five patients included
with AD had infection at inclusion (spontaneous bacterial perito-
nitis [n = 3]; spontaneous bacterial peritonitis and urinary tract
infection [n = 2]) and six patients included were on immunosup-
pressive therapy (steroids for AD [n = 3]/adrenal insufficiency [n =
1]/allergy [n = 1]; azathioprine for autoimmune hepatitis [n = 2]).
Blood specimens were obtained for ex vivo analysis of monocyte
differentiation and function, excessive plasma/serum, and PBMCs
were stored. Patients were followed-up for 1 yr for adverse events
(infection, development of AD after inclusion, mortality, trans-
plantation, and HCC). Evidence of culture-positive/negative in-
fection was documented. The study had been approved by the local
ethics committees (EKSG 15/074/EKNZ 2015-308) and recorded in
the clinical trial register ClinicalTrials.gov (identifier: NCT04116242)
and Swiss National Clinical Trials Portal (SNCTP000003482).
Clinical, haematologic, and biochemical parameters
Routine clinical and laboratory parameters obtained by the clini-
cian such as full blood count, CRP, INR, liver, and renal function
tests and other variables were entered prospectively into a data-
base. Differential blood count at the sites was performed using
Sysmex XE differential analyser (Sysmex Europe GmbH) (Cantonal
Hospital St. Gallen) and ADVIA 2120i hematology systems (Siemens
Healthineers) (University Hospital Basel).
Monocyte isolation
Monocytes were isolated from PBMCs using CD14 MicroBeads or Pan
Monocyte Isolation Kit (Miltenyi Biotec) as previously described (18).
Purity of monocytes was assessed by flow cytometry.
Flow cytometry–based phenotyping of monocytes, assessment of
intracellular cytokine responses to LPS stimulation, and viability
assay
Phenotyping of monocytes from blood and isolated PBMCs and
measurement of inflammatory cytokine production in response to LPS
was undertaken using flow cytometry as previously described (18).
Antibodies against CD14, CD16, CD163, CD64, CD11b, chemokine receptor
(CCR)5, CCR7 (BD Biosciences), CD32, CX3CR1, TLR2, TLR9 (eBioscience),
TLR3 (Invitrogen), HLA-DR, CD15, TLR4, TNF-α, IL-6 (BioLegend), TYRO3,
AXL, MERTK, and IFNAR (R&D Systems) were purchased from the in-
dicated companies. In addition to ex vivo phenotyping, TNF-α and IL-6
levels were determined after a 5 h incubation of PBMCs with LPS (100
ng/ml) (Invivogen) in X- VIVO medium without complements (Fig S11;
Lonza) in a 37°C, 5% CO2 environment. The Cells were subsequently
acquired on BD FACS Canto or BD LSR Fortessa. Flow cytometric gating
strategy for circulating monocytes using whole blood or PBMCs was
applied as described in reference 48. Flow cytometry data were
analysed using FlowJo software (V.10.4.2; Ashland). Results are
expressed as the percentage of positive cells and/or MFI.
Cell viability was determined using the Annexin V Apoptosis
Detection Kit I (including 7-AAD) according tomanufacturer’s protocols
(BD Biosciences).
Formula for calculating absolute numbers of TYRO3/AXL/
MERTK–expressing cells and M-MDSCs
Absolute cell numbers were calculated with the formula: Frequency
of TYRO3/AXL/MERTK-expressing monocytes or M-MDSCs (% defined
by flow cytometry) × monocyte count (G/L).
sAXL, AXL ligands, and cytokines
sAXL (Abcam), GAS6 (Abnova), IL-6, and TNF-α (R&D Systems) were
measured using ELISA in plasma or cell culture supernatants as
previously described (18).
Mixed lymphocyte reaction
Monocytes from HCs and patients with cirrhosis expressing high
(>20%/450 MFI) versus low (<7.5%/300 MFI) AXL levels were isolated
AXL+ monocytes alter immune function in cirrhosis Brenig et al. https://doi.org/10.26508/lsa.201900465 vol 3 | no 1 | e201900465 12 of 16
using the Pan Monocyte Isolation Kit (Miltenyi Biotec) and co-
cultured with allogeneic CD3+ T cells from a different healthy donor,
isolated using the Pan T Cell Isolation Kit (Miltenyi Biotec), in a
1:1 ratio. T cell stimulation was induced with anti-CD2/CD3/CD28
beads (T cell Activation/Expansion Kit; Miltenyi Biotec) as pre-
viously described (20). T cells were stained with carboxyfluorescein
succinimidyl ester at day 0. Proliferation was assessed at day 2 of
co-culture by flow cytometry.
Generation of THP-1 cells stably expressing AXL
pWZL-Neo-Myr-Flag-AXL vector was a kind gift from Hahn’s labo-
ratory (#20428; Addgene). Packaging plasmids pUMVC and pMD2.G
(a gift from Weinberg’s and Trono’s laboratories; #8449 and #12259;
Addgene) were used for the production of the retrovirus. THP-1 cells
were transduced with pWZL-Neo-Myr-Flag-AXL vector, the cells
were selected by G418 (Sigma-Aldrich), and THP-1-AXL+ cells with
stably introduced pWZL-Neo-Myr-Flag-AXL were subcloned using
MethoCult (StemCell Technologies). The clone with highest AXL
expression (for purity see Fig S8) was chosen for phenotypic
characterisation by flow cytometry, gene expression analysis by
quantitative RT-PCR, and LPS-induced cytokine measurement by
ELISA. THP-1 and THP-1-AXL+ cell lines were cultivated in Roswell
Park Memorial Institute 1640 medium (RPMI 1640) (Sigma-Aldrich)
supplemented with 10% heat-inactivated FBS, 100 μg/ml strepto-
mycin, and 100 U/ml penicillin (Sigma-Aldrich).
Quantitative RT-PCR
Total RNA of isolated monocytes from patients with cirrhosis, HCs,
and THP-1/THP-1-AXL+ cells in cell culture was isolated using
RNeasy Mini Kit (QIAGEN) and reversely transcribed into cDNA using
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems/
Thermo Fisher Scientific). qRT-PCR was performed with 400 ng of
cDNA using LightCycler 480 SYBR Green I Master Mix (Roche).
Commercial primers for AXL (Hs_AXL_1_SG QuantiTect Primer Assay)
were purchased from QIAGEN. Sequences (59-39) of primers are as
follows: SOCS1 forward: CCC CTT CTG TAG GAT GGT AGC A; reverse: TGC
TGT GGA GAC TGC ATT GTC and SOCS3 forward: ATG GTC ACC CAC AGC
AAG TT; reverse: TCA CTG CGC TCC AGT AGA AG. GAPDH was used as
endogenous control as previously described (35). qRT-PCR was
performed according to the manufacturer’s recommendations on
QuantStudio Real-Time PCR (Applied Biosystems/Thermo Fisher
Scientific).
Whole blood phagocytosis assay
Whole blood was incubated with pHrodo E. coli Red BioParticles
(Phagocytosis Kit for Flow Cytometry from Invitrogen/Thermo Fisher
Scientific) and live E. coli NovaBlue carrying the gfp-mut2 encoding
plasmid pCD353, which expresses a prokaryotic variant of GFP
controlled by a lactac promoter as described in (49) (a kind gift of
Prof Dr C Dehio, University of Basel). 5 μl of E. coli Red BioParticles
were added for 15 min at 37°C to 100 μl of whole blood and pro-
cessed as previously described (20). Blood with bioparticles was
stained with antibodies against CD14, CD16, HLA-DR, AXL, and CD15,
and CD3, CD19, and CD56 (BD Biosciences) and acquired on the flow
cytometer. E. coli bacteria were freshly grown on LB Agar plates
supplemented with kanamycin (50 μg/ml; Sigma-Aldrich) and in-
cubated overnight at 37°C. A single colony was picked and grown in
LB medium supplemented with kanamycin (50 μg/ml) and IPTG
(1 mM; Sigma-Aldrich) for GFP induction at 37°C until early logarithmic
growth (OD600 = 0.5–0.6) was reached. After the incubation period,
bacteria (1 × 109 bacteria) were centrifuged at 3000g for 5min at 4°C,
resuspended in 1 ml PBS, and used immediately. 5 × 107 of GFP-
containing E. coli were added for 60 min at 37°C to 100 μl of whole
blood and processed as previously described (20). Blood with GFP-
containing E. coli was stained with antibodies against CD14, CD16,
and AXL and acquired on the flow cytometer. The rate of phago-
cytosis was obtained by the proportion of GFP positive monocytes.
In vitro inhibition of AXL
A small-molecule inhibitor of AXL, BGB324 (Selleck Chemicals), and
metformin (Stemcell Technologies) were used. Selectivity and
mechanism of BGB324 were described previously (27, 38). Metformin
was previously described to suppress AXL expression at a con-
centration of 10 mM (28). We used 0.5 × 106 PBMCs from HCs and
patients per well on a 48-well plate and cultured them in X-VIVO
medium (Lonza) containing 10% FBS in a 37°C, 5% CO2 environment.
The cells were treated with 1 μM BGB324/10 mM metformin or
dimethyl sulfoxide/PBS for 24 h, harvested, and washed two times
with PBS before the assessment of inflammatory cytokine pro-
duction in response to LPS (100 ng/ml, 5 h), phagocytosis capacity,
and viability of monocytes by flow cytometry. For the assessment of
monocyte phagocytosis from isolated PBMCs in vitro, the harvested
cells were incubated with pHrodo E. coli Red BioParticles
(Invitrogen/Thermo Fisher Scientific) for 60 min, processed, and
assessed by flow cytometry as previously described (20). The op-
timal dose of 1 μM BGB324 was initially defined by a dose finding
experiment assessing cytokine production of monocytes in re-
sponse to LPS (100 ng/ml, 5 h). Cell viability using Annexin V (BD
Biosciences) was assessed after BGB324 and metformin treatment
(Fig S10B–D).
In vitro models for the generation of AXL-expressing cells
1 × 106 PBMCs per well were cultured on 24-well plates in 1 ml X-VIVO
medium (Lonza) in a 37°C, 5% CO2 environment. Cells were stim-
ulated with or without LPS 100 ng/ml (4, 8, 16, 18, 24 h), Pam3CSK4 5
μg/ml, CpG 10 μg/ml, poly(I:C) 10 μg/ml (Invivogen), IFN-α 250 U/ml
(Roche), TNF-α 250 U/ml, GAS6 20 nM (R&D Systems), HMGB1 20 ng/ml
(Sigma-Aldrich), and TGF-β 2 ng/ml (PeproTech) for 18 h. The cells
were harvested and subjected to immunophenotyping, intracellular
staining of cytokine production in response to LPS and viability assays
using flow cytometry as described before.
For the experiments incubating healthy monocytes in plasma
from HC (n = 4) and patients with cirrhosis (n = 4), 1 × 106 CD14+ cells
were cultured in a 24-well plate for 24 h in X-VIVO medium (Lonza)
containing 25% of the indicated plasma in a 37°C, 5% CO2 envi-
ronment. Subsequently, a fraction of these cells was phenotyped
and the remainder was transferred to fresh medium for the as-
sessment of LPS-stimulated TNF-α/IL6 production and phagocy-
tosis capacity of monocytes by flow cytometry as detailed before.
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For the experiments measuring AXL-expressing monocytes after
treatment of bacteria, whole blood was incubated with pHrodo E.
coli Red BioParticles, pHrodo S. aureus Red BioParticles (Invitrogen/
Thermo Fisher Scientific) for 15min, andwith live GFP-containing E. coli
bacteria for 60 min and processed as described above.
Efferocytosis assay
The experimental design was adapted from Zizzo et al (26) and
Triantafyllou et al (19). Human neutrophils were isolated using
PolymorphPrep (Axis-Shield) by density-gradient centrifugation
according to the manufacturer’s protocols, re-suspended at 1 × 106
cells/ml in RPMI-1640 (Sigma-Aldrich) containing 10% FBS (com-
plete medium), labelled with CellTracker Violet BMQC (5 μM in
serum-free medium, 45 min, 37°C, dark; Life Technologies, Thermo
Fisher Scientific), and incubated for 20 h (37°C in 5% CO2) in 300 μl
complete RPMI-1640 in 24-well plates. HepG2 cells were seeded at
0.4 × 106 cells/ml in 24-well plates, labelled with CellTracker Violet
BMQC as described above, and incubated with LPS (1 μg/ml) for 18 h
(37°C in 5% CO2) in 300 μl complete RPMI-1640. After the incubation
period, percentage of apoptotic neutrophils and HepG2 cells in
culture was determined using Annexin V Apoptosis Detection Kit I
according to the manufacturer’s protocols (BD Biosciences). Neu-
trophils and HepG2 cells were re-suspended in the wells and
healthy monocytes were added to apoptotic cells (1:4 monocytes to
apoptotic cells ratio) for 8 h in 1 ml fresh complete RPMI-1640 (37°C
in 5% CO2). The cells were harvested and washed two times in PBS
and subjected to immunophenotyping, intracellular staining of
cytokine production in response to LPS (100 ng/ml, 5 h), and via-
bility assays as described above. The rate of efferocytosis was
obtained by the proportion of CellTracker-positive monocytes.
Statistical analyses
Statistical evaluation was performed in GraphPad Prism v.7.0a
(GraphPad Software). P < 0.05 values were considered statistically
significant. Data are shown as box and whiskers or scatter dot plots
and expressed as median with 10–90 percentile, unless otherwise
specified. For data that did not follow a normal distribution, sig-
nificance of differences was tested using Mann–Whitney or Wil-
coxon tests. Spearman correlation coefficients and area under the
receiver operating characteristic curve were calculated. Normally
distributed data were compared using paired or unpaired t-tests.
Supplementary Information
Supplementary Information is available at https://doi.org/10.26508/lsa.
201900465.
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